Herantis Pharma
1.78 EUR
+0.11 %
4,557 following
Corporate customer
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
Valuation
Income statement
Quarterly estimates
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Herantis Pharma
P/E (adj.)
Median 2021-2025
EV/EBIT (adj.)
Median 2021-2025
Dividend yield
Median 2021-2025
P/B
Median 2021-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 7.37 | 4.15 | 2.40 | 1.65 | 1.58 | 1.52 | 2.04 | 1.78 | 1.78 | 1.78 | 1.78 |
| Shares | 9.8 | 11.1 | 16.9 | 20.2 | 20.2 | 24.1 | 34.8 | 34.8 | 34.8 | 34.8 | |
| Market cap | 40.5 | 26.6 | 27.9 | 31.9 | 30.6 | 49.2 | 62.1 | 62.1 | 62.1 | 62.1 | |
| Enterprise value | 34.4 | 26.4 | 26.5 | 25.4 | 28.5 | 46.6 | 52.4 | 59.8 | 68.5 | 83.0 | |
| EV/S | - | 8,593.4 | 6,606.4 | 6,613.7 | 6,360.3 | 2,854.0 | 4,658.3 | 5,237.0 | 5,981.0 | 6,852.2 | 8,304.0 |
| EV/EBITDA | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT (adj.) | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | - | neg. | neg. | neg. | 165.2 | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E (adj.) | - | neg. | neg. | neg. | 114.2 | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E | - | neg. | neg. | neg. | 114.2 | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | - | 5.3 | neg. | neg. | 6.8 | neg. | neg. | 6.2 | 24.6 | neg. | neg. |
| P/S | - | 10,122.9 | 6,662.4 | 6,976.2 | 7,963.6 | 3,064.5 | 4,915.4 | 6,208.0 | 6,208.0 | 6,208.0 | 6,208.0 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 46.2 % | -14.7 % | -1.1 % | 69.9 % | -11.4 % | -63.3 % | 100.0 % | 100.0 % | -2,474.6 % | -8,277.4 % | |
| Gearing ratio | -80.6 % | 19.6 % | 2,071.4 % | -136.0 % | 718.4 % | 152.1 % | -97.5 % | -90.1 % | -104.0 % | -101.2 % |